We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Problems Surface in US Plan to Vaccinate for Smallpox

By Biotechdaily staff writers
Posted on 04 Feb 2003
Following an announcement by the US government that voluntary vaccinations of health care workers against smallpox would begin this month, concerns and objections are arising from many of those scheduled for inoculation.

The first phase of the vaccination program calls for up to 500,000 health care workers to be vaccinated in the coming weeks. More...
A later, second phase would include first responders such as police, firefighters, and emergency medical personnel. However, many of those scheduled to be vaccinated have refused and many health care workers are voicing concerns and questions.

One concern is the safety of the vaccine. When the vaccine was last used in the 1960s, there were two deaths and 52 life-threatening complications for every million people who were vaccinated. The vaccine employs the vaccinia virus, which is related to smallpox. There is a possibility that the virus may shed from the site of inoculation and infect others. This could be dangerous to those who are especially vulnerable, such as babies and people who have compromised immune systems. One important question raised is if a vaccinated health care worker has a bad reaction and cannot work for a number of days, who will pay for that time? Still another problem is the cost of the program. Many healthcare workers say the government is seriously underestimating the costs of the program, which also have to include training, screening out people at risk, following up on people with bad reactions, and managing the data from the program.

As a result, many of the hospitals and medical centers that had scheduled vaccinations are now reporting they are delaying any further involvement in the program until they have more information and can answer everyone's concerns.

"At this time, our highest priority is to vaccinate members of smallpox response teams in the states,” said Dr. Julie Gerberding, director of the US Centers for Disease Control and Prevention (CDA, Atlanta, GA, USA). "Several months of detailed planning and training, and the development of scientifically sound and informative educational materials have prepared us for the safe and rapid implementation of the plan to vaccinate those health care professionals who would be on the front lines in the event of a smallpox attack.”




Related Links:
US Centers for Disease Control and Prevention (CDC)

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.